Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01736943 · ClinicalTrials.gov registry record · Phase 2
Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia
A Phase 2 study, sponsored by Joseph Tuscano.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01736943: Completed Phase 2 study, sponsored by Joseph Tuscano.
NCT01736943 is a Phase 2 study that has completed, run by Joseph Tuscano. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01736943, a Phase 2 study, has completed, sponsored by Joseph Tuscano.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether bortezomib in combination with doxil/lipodox is effective in the treatment of Acute Myeloid Leukemia.
Primary Outcome
The time from first day of treatment to the first observation of disease progression or death due to any cause. If a patient has not progressed or died, progression-free survival is censored at the time of last follow-up.
Interventions
- DRUG Doxil
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-12-19 |
| Est. Completion | 2019-05-20 |
| Phase | Phase 2 |
What the finished NCT01736943 record still lists
NCT01736943 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Doxil is the first listed.
NCT01736943 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01736943 about?
NCT01736943 is a clinical study titled "Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia". The purpose of this study is to determine whether bortezomib in combination with doxil/lipodox is effective in the treatment of Acute Myeloid Leukemia.
What is the current status of trial NCT01736943?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2012-12-19. Estimated completion is 2019-05-20.
What interventions are being tested in trial NCT01736943?
The interventions under investigation include: Doxil (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT01736943?
This trial is sponsored by Joseph Tuscano, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01736943's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI